Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 407-418

  Ramirez, Andrea H ^a   Shi, Yaping ^a   Schildcrout, Jonathan S ^a   Delaney, Jessica T ^a   Xu, Hua ^b   Oetjens, Matthew T ^b   Zuvich, Rebecca L ^b   Basford, Melissa A ^a   Bowton, Erica ^a   Jiang, Min ^b   Speltz, Peter ^b   Zink, Raquel ^b   Cowan, James ^a   Pulley, Jill M ^a   Ritchie, Marylyn D ^b,c   Masys, Daniel R ^b   Roden, Dan M ^a   Crawford, Dana C ^b,c   Denny, Joshua C ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticoagulants; bioinformatics; electronic health record; genes; pharmacogenomics; warfarin

Indexed keywords

WARFARIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CALU GENE; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DOSE CALCULATION; DRUG DOSE COMPARISON; ELECTRONIC MEDICAL RECORD; EUROPEAN AMERICAN; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICATION ERROR; PHARMACOGENETICS; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM-BINDING PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRONIC HEALTH RECORDS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTANCE-RELATED DISORDERS; WARFARIN;

EID: 84863229218     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.164     Document Type: Article

References (53)

1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414-1419 (2007).
2. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
3. Kurnik D, Loebstein R, Halkin H, Gak E, Almog S. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 10(12), 1955-1965 (2009).
4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
5. Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004).
6. McClain MR, Palomaki GE, Piper M, Haddow JE. A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet. Med.10(2), 89-98 (2008).
7. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
8. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11(9), 803-808 (2001).
9. Blaisdell J, Mohrenweiser H, Jackson J et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12(9), 703-711 (2002).
10. Voora D, Koboldt DC, King CR et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 445-451 (2010).
11. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
12. Loebstein R, Vecsler M, Kurnik D et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77(5), 365-372 (2005).
13. Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5(4), 262-270 (2005).
14. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
15. Pautas E, Moreau C, Gouin-Thibault I et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87(1), 57-64 (2009).
16. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5(11), 2227-2234 (2007).
17. Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010).
18. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
19. Schelleman H, Chen Z, Kealey C et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81(5), 742-747 (2007).
20. Limdi NA, Arnett DK, Goldstein JA et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5), 511-526 (2008).
21. Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
22. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. Ann. Intern. Med. 133(9), 687-695 (2000).
23. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
24. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
25. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
26. Ritchie MD, Denny JC, Crawford DC et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86(4), 560-572 (2010).
27. Roden DM, Pulley JM, Basford MA et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84(3), 362-369 (2008).
28. Pulley J, Clayton E, Bernard GR, Roden DM, Masys DR. Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin. Transl. Sci. 3(1), 42-48 (2010).
29. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17(1), 19-24 (2010).
30. Dumitrescu L, Ritchie MD, Brown-Gentry K et al. Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet. Med. 12(10), 648-650 (2010).
31. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
32. Grady BJ, Torstenson E, Dudek SM, Giles J, Sexton D, Ritchie MD. Finding unique filter sets in plato: a precursor to efficient interaction analysis in GWAS data. Pac. Symp. Biocomput. 315-326 (2010).
33. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
34. Delaney J, Ramirez A, Bowton E et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91(2), 257-263 (2012).
35. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12(1), 125-134 (2011).
36. Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy 31(9), 863-870 (2011).
37. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12(3), 283-291 (2010).
38. Zambon C-F, Pengo V, Padrini R et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12(1), 15-25 (2011).
39. Wells PS, Majeed H, Kassem S et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 125(6), e259-e264 (2010).
40. Lubitz SA, Scott SA, Rothlauf EB et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8(5), 1018-1026 (2010).
41. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57(5), 612-618 (2011).
42. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150(2), 73-83 (2009).
43. Khan N, Peterson J. A surveillance tool to support quality assuranceand research in personalized medicine. Presented at: The 2011 American Medical Informatics Association Annual Symposium. Washington, DC, USA, 22-26 October 2011.
44. Schildcrout J, Denny J, Bowton E et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Presented at: The 12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics. Montreal, Canada 11-15 October 2011.
45. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
46. Perera MA, Gamazon E, Cavallari LH et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin. Pharmacol. Ther. 89(3), 408-415 (2011).
47. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 160S-198S (2008).
48. Caraco Y, Blotnick S, Muszkat M. CYP2C9 Genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2007).
49. Wen M-S, Lee M, Chen J-J et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84(1), 83-89 (2008).
50. Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6), 509-518 (2011).
51. McMillin GA, Melis R, Wilson A et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther. Drug Monit. 32(3), 338-345 (2010).
52. French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
53. van Schie RMF, Wadelius MIA, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).